MyFinsight
Home
Blog
About
Contact
Download
Download image
Net loss
attributable to adaptive...
-$59,499K
(62.69%↑ Y/Y)
Service
$192,834K
(44.96%↑ Y/Y)
Regulatory Milestone
Revenue
$19,500K
(56.00%↑ Y/Y)
Collaboration Revenue
$41,282K
(206.88%↑ Y/Y)
Service And Licensing
Revenue
$23,360K
Net loss
-$59,457K
(62.75%↑ Y/Y)
Add net (income)
loss attributable to...
$42K
(140.78%↑ Y/Y)
Interest and other
income, net
$9,444K
(-35.02%↓ Y/Y)
MRDRevenue
$212,334K
(45.90%↑ Y/Y)
Immune Medicine
Revenue
$64,642K
(93.38%↑ Y/Y)
Loss from operations
-$57,123K
(64.86%↑ Y/Y)
Interest expense
$11,778K
(1.71%↑ Y/Y)
Revenue
$276,976K
(54.77%↑ Y/Y)
Total operating
expenses
$334,099K
(-2.17%↓ Y/Y)
Sales and marketing
$94,571K
(11.58%↑ Y/Y)
Research and development
$93,769K
(-8.92%↓ Y/Y)
General and
administrative
$72,701K
(-0.14%↓ Y/Y)
Cost of revenue
$71,359K
(-1.00%↓ Y/Y)
Amortization of intangible
assets
$1,699K
(-0.23%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Adaptive Biotechnologies Corp (ADPT)
Adaptive Biotechnologies Corp (ADPT)